(E)-N-[2-hydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-3-yl]ethanimidic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-N-[2-hydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-3-yl]ethanimidic acid
• 英文别名: N-[2-hydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-3-yl]acetamide
• 化学式: C₂₀H₃₅NO₁₅
• 分子量: 529.5
• InChiKey: HBBOZFUQJDYASD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.8
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  257
• 氢给体数：
  10
• 氢受体数：
  15

文献信息

• Methods for modular synthesis of N-glycans and arrays thereof
  申请人：Academia Sinica

  公开号：US10336784B2

  公开（公告）日：2019-07-02

  The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycans and glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.

  本公开涉及一种新颖的模块化方法，用于生成多种高甘露糖、混合型和复合型 N-聚糖。本公开内容还涉及将合成的 N-聚糖点缀在涂有氧化铝的载玻片上的示例阵列。这些阵列可用于检测和分析合成的 N-聚糖与聚糖结合分子（如 HIV-1 中和抗体）之间的结合相互作用。本公开内容还涉及识别与阵列上各类分子结合的制剂的方法，以及确定阵列上与这些制剂结合的分子的结构元素的方法。本文提供的阵列和方法可用于一般表位鉴定、药物发现和分析工具。本公开内容还提供了有用的聚糖和表位决定因子，可用于检测、诊断、复发监测和预防艾滋病毒等病理疾病。
• Compositions and methods for treatment of inflammatory disorders
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US10668092B2

  公开（公告）日：2020-06-02

  The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.

  本发明涉及通过施用新发现的具有 TLR4 抑制活性的各种化合物来治疗感染性、炎症性和创伤后疾病的方法。除治疗方法外，本发明还进一步提供了药物组合物，其中包含上述化合物以及合适的药物载体。
• ANTAGONISTE SPÉCIFIQUE DE TLR4 DANS LE TRAITEMENT DU MYÉLOME MULTIPLE
  申请人：Etablissement Français du Sang

  公开号：EP3558323A1

  公开（公告）日：2019-10-30
• COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20180280418A1

  公开（公告）日：2018-10-04

  The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.
• SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA
  申请人：Etablissement Français du Sang

  公开号：US20220023325A1

  公开（公告）日：2022-01-27

  The present invention relates to a TLR4 (toll-like receptor 4) specific antagonist for use in the treatment of multiple myeloma in a subject suffering from multiple myeloma, and also to an antitumor pharmaceutical combination comprising (i) a TLR4-specific antagonist and (ii) a chemotherapy agent for simultaneous, separate or sequential use in the treatment of multiple myeloma.